Squarepoint’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-73,394
Closed -$10.1M 4597
2025
Q3
$6.87M Sell
73,394
-87,752
-54% -$6.2M 0.01% 1275
2025
Q2
$9.17M Buy
161,146
+40,157
+33% +$2.13M 0.01% 1114
2025
Q1
$7.38M Buy
120,989
+24,667
+26% +$2.1M 0.01% 1188
2024
Q4
$8.67M Buy
96,322
+92,563
+2,462% +$10.9M 0.01% 1243
2024
Q3
$484K Sell
3,759
-23,344
-86% -$3.05M ﹤0.01% 3122
2024
Q2
$3.07M Sell
27,103
-10,290
-28% -$1.1M 0.01% 1724
2024
Q1
$4.96M Sell
37,393
-23,845
-39% -$3.11M 0.01% 1445
2023
Q4
$7.47M Buy
61,238
+41,019
+203% +$3.14M 0.01% 1119
2023
Q3
$1.54M Sell
20,219
-13,317
-40% -$1.37M ﹤0.01% 2017
2023
Q2
$3.97M Buy
33,536
+15,819
+89% +$1.97M 0.01% 1216
2023
Q1
$1.74M Buy
+17,717
New +$2.4M 0.01% 1508
2022
Q3
Sell
-3,303
Closed -$445K 3221
2022
Q2
$445K Buy
+3,303
New +$563K ﹤0.01% 2070
2022
Q1
Sell
-1,294
Closed -$932K 3217
2021
Q4
$932K Buy
+1,294
New +$1.24M ﹤0.01% 1742

Other funds holding LABU

Squarepoint's LABU Position: Q4 2025 in Review

Squarepoint sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q4 2025, closing a stake of 73,394 shares — an estimated $10.1M sold.

Squarepoint first reported a position in LABU in Q4 2021 and held it in 13 quarters. The position peaked at $9.17M in Q2 2025. 40 funds tracked by Wall St. Rank hold LABU as of Q4 2025.

  • Squarepoint reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 73,394 Direxion Daily S&P Biotech Bull 3X ETF shares in Q4 2025, an estimated $10.1M.
  • Squarepoint first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q4 2021 and held it in 13 quarters.
  • Squarepoint's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $9.17M in Q2 2025.
  • 40 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.